Industry top-down
Drug Manufacturers - General
Latest reported revenue & EPS across the covered companies in this industry, with year-over-year (YoY) change. From disclosed earnings — not investment advice.
AI industry top-down
The pharmaceutical industry showed varying performance across companies. Amgen and AbbVie recorded robust sales growth of 9.43% and 8.39% respectively, while Pfizer underperformed with a 7.82% decrease. EPS also showed significant divergence among companies, with Merck growing by 7.49% while Biogen saw a 39.26% decrease. The median sales growth rate for the entire industry was -0.28%, indicating mixed performance among individual companies within an overall stagnant trend.
- Some companies show strong revenue growth (ABBV, AMGN, BIIB revenue increased)
- Other companies experienced revenue decrease or stagnation (PFE, BMY, MRK, GILD revenue decreased/stagnated)
- Mixed EPS growth rates by company (MRK grew, ABBV, PFE, BIIB decreased)
- Industry median revenue YoY is flat (-0.28%)
AI synthesis of disclosed results and analyst research across these companies — not investment advice.
Companies — latest quarter
| Company | Period | Revenue | Rev YoY | EPS | EPS YoY | Surprise |
|---|---|---|---|---|---|---|
| ABBVAbbVie Inc. | FY2026 Q1 | $13.34B | +8.4% | $0.72 | -6.5% | — |
| MRKMerck & Co., Inc. | FY2026 Q1 | $15.53B | -1.6% | $2.01 | +7.5% | — |
| AMGNAMGEN INC | FY2026 Q1 | $8.15B | +9.4% | $3.20 | — | — |
| GILDGILEAD SCIENCES, INC. | FY2026 Q1 | $6.67B | -0.3% | $1.04 | — | — |
| PFEPFIZER INC | FY2026 Q1 | $13.72B | -7.8% | $0.52 | -5.5% | — |
| BMYBRISTOL MYERS SQUIBB CO | FY2026 Q1 | $11.2B | -5.6% | $1.20 | — | — |
| BIIBBIOGEN INC. | FY2026 Q1 | $2.43B | +6.1% | $1.64 | -39.3% | — |
| OGNOrganon & Co. | FY2026 Q1 | $1.51B | -6.7% | $0.33 | -57.7% | — |
| AMRNAMARIN CORP PLCUK | FY2026 Q1 | $42.02M | -25.7% | $-0.04 | — | — |
| 464280TDSPHARM Co., Ltd. | FY2026 Q1 | ₩8.07B | +52.9% | ₩217.00 | +214.5% | — |
| 307750KUKJEON Co.,Ltd | FY2025 Q3 | ₩29.2B | — | ₩-58.00 | — | — |
YoY = vs. the same quarter last year · Surprise = EPS actual vs. consensus. Latest reported quarter per company, from disclosed earnings filings. QoQ is omitted because quarterly filings don’t break out Q4 (US) and report cumulatively (KR).